, the only effective drugs for the treatment of tumor syndrome in NF1 are inhibitors of mitogen-
activatedAhmad, S.,
Abbas, M.,
Ullah, M.F.,
Aziz, M.H.,
Beylerli, O.,
Alam, M.A.,
Syed, M.A.,
Uddin, S.,
Ahmad, A. (2022) consistently shown to inhibit NF-κB
activation via inhibition of IκBα phosphorylation and the resulting
Gareev, I,
Beylerli, O,
Wang, CL,
Sokhatskii, A,
Liang, YC,
Xiang, H,
Liu, CY,
Xu, X,
Guang, Y (2022) fluids. Owing to their stability and resistance to endogenous RNase
activity, circulating miRNAs have